481 related articles for article (PubMed ID: 32715349)
21. KRAS G12C inhibition and innate immune targeting.
Tani T; Kitajima S; Conway EB; Knelson EH; Barbie DA
Expert Opin Ther Targets; 2021 Mar; 25(3):167-174. PubMed ID: 33703985
[TBL] [Abstract][Full Text] [Related]
22. Selective apoptosis-inducing activity of synthetic hydrocarbon-stapled SOS1 helix with d-amino acids in H358 cancer cells expressing KRAS
Xu LL; Li CC; An LY; Dai Z; Chen XY; You QD; Hu C; Di B
Eur J Med Chem; 2020 Jan; 185():111844. PubMed ID: 31706640
[TBL] [Abstract][Full Text] [Related]
23. Identification of MRTX1133, a Noncovalent, Potent, and Selective KRAS
Wang X; Allen S; Blake JF; Bowcut V; Briere DM; Calinisan A; Dahlke JR; Fell JB; Fischer JP; Gunn RJ; Hallin J; Laguer J; Lawson JD; Medwid J; Newhouse B; Nguyen P; O'Leary JM; Olson P; Pajk S; Rahbaek L; Rodriguez M; Smith CR; Tang TP; Thomas NC; Vanderpool D; Vigers GP; Christensen JG; Marx MA
J Med Chem; 2022 Feb; 65(4):3123-3133. PubMed ID: 34889605
[TBL] [Abstract][Full Text] [Related]
24. Concurrent inhibition of oncogenic and wild-type RAS-GTP for cancer therapy.
Holderfield M; Lee BJ; Jiang J; Tomlinson A; Seamon KJ; Mira A; Patrucco E; Goodhart G; Dilly J; Gindin Y; Dinglasan N; Wang Y; Lai LP; Cai S; Jiang L; Nasholm N; Shifrin N; Blaj C; Shah H; Evans JW; Montazer N; Lai O; Shi J; Ahler E; Quintana E; Chang S; Salvador A; Marquez A; Cregg J; Liu Y; Milin A; Chen A; Ziv TB; Parsons D; Knox JE; Klomp JE; Roth J; Rees M; Ronan M; Cuevas-Navarro A; Hu F; Lito P; Santamaria D; Aguirre AJ; Waters AM; Der CJ; Ambrogio C; Wang Z; Gill AL; Koltun ES; Smith JAM; Wildes D; Singh M
Nature; 2024 May; 629(8013):919-926. PubMed ID: 38589574
[TBL] [Abstract][Full Text] [Related]
25. Targeting mutant KRAS.
Erlanson DA; Webster KR
Curr Opin Chem Biol; 2021 Jun; 62():101-108. PubMed ID: 33838397
[TBL] [Abstract][Full Text] [Related]
26. Inhibition of RAS: proven and potential vulnerabilities.
Zuberi M; Khan I; O'Bryan JP
Biochem Soc Trans; 2020 Oct; 48(5):1831-1841. PubMed ID: 32869838
[TBL] [Abstract][Full Text] [Related]
27. Targeting Mutant KRAS for Anticancer Therapy.
Chen F; Alphonse MP; Liu Y; Liu Q
Curr Top Med Chem; 2019; 19(23):2098-2113. PubMed ID: 31475898
[TBL] [Abstract][Full Text] [Related]
28. More to the RAS Story: KRAS
Lietman CD; Johnson ML; McCormick F; Lindsay CR
Am Soc Clin Oncol Educ Book; 2022 Apr; 42():1-13. PubMed ID: 35561303
[TBL] [Abstract][Full Text] [Related]
29. Chemical remodeling of a cellular chaperone to target the active state of mutant KRAS.
Schulze CJ; Seamon KJ; Zhao Y; Yang YC; Cregg J; Kim D; Tomlinson A; Choy TJ; Wang Z; Sang B; Pourfarjam Y; Lucas J; Cuevas-Navarro A; Ayala-Santos C; Vides A; Li C; Marquez A; Zhong M; Vemulapalli V; Weller C; Gould A; Whalen DM; Salvador A; Milin A; Saldajeno-Concar M; Dinglasan N; Chen A; Evans J; Knox JE; Koltun ES; Singh M; Nichols R; Wildes D; Gill AL; Smith JAM; Lito P
Science; 2023 Aug; 381(6659):794-799. PubMed ID: 37590355
[TBL] [Abstract][Full Text] [Related]
30. Quantitative Systems Pharmacology Analysis of KRAS G12C Covalent Inhibitors.
Stites EC; Shaw AS
CPT Pharmacometrics Syst Pharmacol; 2018 May; 7(5):342-351. PubMed ID: 29484842
[TBL] [Abstract][Full Text] [Related]
31. KRAS G12C Drug Development: Discrimination between Switch II Pocket Configurations Using Hydrogen/Deuterium-Exchange Mass Spectrometry.
Lu J; Harrison RA; Li L; Zeng M; Gondi S; Scott D; Gray NS; Engen JR; Westover KD
Structure; 2017 Sep; 25(9):1442-1448.e3. PubMed ID: 28781083
[TBL] [Abstract][Full Text] [Related]
32. KRAS
Lou K; Steri V; Ge AY; Hwang YC; Yogodzinski CH; Shkedi AR; Choi ALM; Mitchell DC; Swaney DL; Hann B; Gordan JD; Shokat KM; Gilbert LA
Sci Signal; 2019 May; 12(583):. PubMed ID: 31138768
[TBL] [Abstract][Full Text] [Related]
33. Drugging an undruggable pocket on KRAS.
Kessler D; Gmachl M; Mantoulidis A; Martin LJ; Zoephel A; Mayer M; Gollner A; Covini D; Fischer S; Gerstberger T; Gmaschitz T; Goodwin C; Greb P; Häring D; Hela W; Hoffmann J; Karolyi-Oezguer J; Knesl P; Kornigg S; Koegl M; Kousek R; Lamarre L; Moser F; Munico-Martinez S; Peinsipp C; Phan J; Rinnenthal J; Sai J; Salamon C; Scherbantin Y; Schipany K; Schnitzer R; Schrenk A; Sharps B; Siszler G; Sun Q; Waterson A; Wolkerstorfer B; Zeeb M; Pearson M; Fesik SW; McConnell DB
Proc Natl Acad Sci U S A; 2019 Aug; 116(32):15823-15829. PubMed ID: 31332011
[TBL] [Abstract][Full Text] [Related]
34. The Research Progress of Direct KRAS G12C Mutation Inhibitors.
Yang A; Li M; Fang M
Pathol Oncol Res; 2021; 27():631095. PubMed ID: 34257597
[No Abstract] [Full Text] [Related]
35. Drugging KRAS: current perspectives and state-of-art review.
Parikh K; Banna G; Liu SV; Friedlaender A; Desai A; Subbiah V; Addeo A
J Hematol Oncol; 2022 Oct; 15(1):152. PubMed ID: 36284306
[TBL] [Abstract][Full Text] [Related]
36. Progress in targeting RAS with small molecule drugs.
McCormick F
Biochem J; 2019 Jan; 476(2):365-374. PubMed ID: 30705085
[TBL] [Abstract][Full Text] [Related]
37. Drugging the Undruggable: Advances on RAS Targeting in Cancer.
Molina-Arcas M; Samani A; Downward J
Genes (Basel); 2021 Jun; 12(6):. PubMed ID: 34200676
[TBL] [Abstract][Full Text] [Related]
38. Covalent targeting of acquired cysteines in cancer.
Visscher M; Arkin MR; Dansen TB
Curr Opin Chem Biol; 2016 Feb; 30():61-67. PubMed ID: 26629855
[TBL] [Abstract][Full Text] [Related]
39. KRAS G12C fragment screening renders new binding pockets.
Mathieu M; Steier V; Fassy F; Delorme C; Papin D; Genet B; Duffieux F; Bertrand T; Delarbre L; Le-Borgne H; Parent A; Didier P; Marquette JP; Lowinski M; Houtmann J; Lamberton A; Debussche L; Alexey R
Small GTPases; 2022 Jan; 13(1):225-238. PubMed ID: 34558391
[TBL] [Abstract][Full Text] [Related]
40. Discovery of AZD4625, a Covalent Allosteric Inhibitor of the Mutant GTPase KRAS
Kettle JG; Bagal SK; Bickerton S; Bodnarchuk MS; Boyd S; Breed J; Carbajo RJ; Cassar DJ; Chakraborty A; Cosulich S; Cumming I; Davies M; Davies NL; Eatherton A; Evans L; Feron L; Fillery S; Gleave ES; Goldberg FW; Hanson L; Harlfinger S; Howard M; Howells R; Jackson A; Kemmitt P; Lamont G; Lamont S; Lewis HJ; Liu L; Niedbala MJ; Phillips C; Polanski R; Raubo P; Robb G; Robinson DM; Ross S; Sanders MG; Tonge M; Whiteley R; Wilkinson S; Yang J; Zhang W
J Med Chem; 2022 May; 65(9):6940-6952. PubMed ID: 35471939
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
